[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"placenta-accreta-spectrum\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:placenta-accreta-spectrum":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,43,72,93,120,142,171,196,221,241,264,294,313,333],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100632939","comparison-between-3-conservative-surgeries-for-placenta-accreta-spectrum-100632939",false,"NCT07520201","Comparison Between 3 Conservative Surgeries for Placenta Accreta Spectrum","Modified One Step Surgery vs. Segment Resection vs. Placental Bed Suturing for Management of Placenta Accreta Spectrum","Inclusion Criteria:\n\n* pregnant women with placenta accreta spectrum\n\nExclusion Criteria:\n\n* Patients refuse to share in the study\n* Pregnant \\\u003C 28 weeks","FEMALE",{"count":18,"type":19},42,"ESTIMATED","INTERVENTIONAL",[22],"NA","Comparison between modified one-step surgery vs. Segment Resection vs. placental bed suturing for management of placenta accreta spectrum",[25],"Placenta Accreta Spectrum",[27,28,29,30],"Segment Resection","Modified one-step","Placental bed plication","Conservative uterine surgery","RECRUITING","2026-06-26",{"date":34,"type":35},"2026-06-30","ACTUAL",{"date":32,"type":35},{"date":38,"type":19},"2027-07",{"name":40,"class":41},"Assiut University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":42},"100643412","diagnostic-trial-of-a-vision-transformer-based-ultrasound-ai-model-for-placenta-accreta-spectrum-100643412","NCT07643090","Diagnostic Trial of a Vision Transformer-Based Ultrasound AI Model for Placenta Accreta Spectrum","Diagnostic Trial of Vision Transformer-Based End-to-End Ultrasound Artificial Intelligence Model for Assisting in the Diagnosis of Placenta Accreta Spectrum Disorders: An Investigator-Initiated Prospective Clinical Study","Inclusion criteria:\n\n1. Pregnant women aged between 18 and 45 years;\n2. Gestational age between 24 and 34 weeks;\n3. Pregnant women with a history of placenta previa;\n4. Pregnant women with an anterior placenta;\n5. Willingness to participate in the study and provision of written informed consent.\n\nExclusion criteria:\n\n1. Failure to provide written informed consent;\n2. Presence of severe complications that precluded continuation of pregnancy;\n3. Inability to comply with study procedures for other reasons.","18 Years","45 Years",{"count":53,"type":19},561,"12 Months","OBSERVATIONAL","This study develops an end-to-end Vision Transformer (ViT)-based artificial intelligence system for ultrasound-based diagnosis of placenta accreta spectrum (PAS), aiming to improve the accuracy and efficiency of prenatal screening using standardized ultrasound video inputs.",[25],[25,59,60,61,62],"Ultrasonography","Artificial Intelligence","Prenatal Diagnosis","Vision Transformer","2026-06-08",{"date":65,"type":35},"2026-06-11",{"date":67,"type":35},"2025-09-01",{"date":69,"type":19},"2027-12-31",{"name":71,"class":41},"FANG HE",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":20,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":42},"100555445","uterine-preservation-in-the-management-of-placenta-accreta-spectrum-disorders-100555445","NCT06512181","Uterine Preservation in the Management of Placenta Accreta Spectrum Disorders","U-PRESERVE","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. A person with a uterus, age 18 or older\n4. Currently pregnant with an intrauterine gestation or postpartum\n5. Suspected of having PAS based on history, clinical findings, and\u002For imaging\n6. Patients for whom the usual management would be peripartum hysterectomy.\n7. Patient desires uterine preservation or declines hysterectomy\n8. Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration.\n\nExclusion Criteria:\n\n• Have a low antenatal suspicion for PAS based on imaging.",{"count":80,"type":19},15,[22],"This study for the conservative management of placenta accreta spectrum disorders (PAS), which are a major cause of maternal morbidity and mortality. The most common management strategy for PAS in the United States is a preterm cesarean-hysterectomy. However, accumulating data show that conservative management is safer and is preferred by some patients. In selected participants (n=15) who desire uterine preservation, the investigators provide the option of conservative management, which will be defined as leaving the placenta in the uterus after delivery of the infant. This is a single-arm single-site pilot study where all participants will be carefully monitored during a standard postpartum inpatient stay and with outpatient follow-up until the uterus is empty.",[25],"2026-05-07",{"date":86,"type":35},"2026-05-11",{"date":88,"type":35},"2025-04-21",{"date":90,"type":19},"2030-12-31",{"name":92,"class":41},"University of Pennsylvania",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":101,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":20,"phases":104,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":42},"100563766","high-vs-low-segmental-hysterotomy-impact-on-uterine-wall-defects-post-cesarean-100563766","NCT06620432","High vs. Low Segmental Hysterotomy: Impact on Uterine Wall Defects Post-Cesarean","High Segmental Hysterotomy vs. Low Segmental Hysterotomy: Association With the Incidence of Uterine Wall Defects After Cesarean Section","HISEAL","Inclusion Criteria:\n\n* Pregnant women aged ≥ 18 years.\n* Confirmed pregnancy through clinical history or ultrasound between 36 and 42 weeks of gestation.\n* Indication by the attending gynecologist for a first cesarean section, either emergent or elective.\n\nExclusion Criteria:\n\n* History of myometrial intervention, such as myomectomy.\n* History of genetic or acquired conditions that alter the anatomy of the uterus.\n* History of coagulation disorders.\n* History of connective tissue disorders, such as Lupus and Scleroderma, which may affect healing.\n* Hemodynamically unstable patients due to a clinical condition prior to performing the cesarean section.\n* Failure to sign the informed consent.",true,{"count":103,"type":19},168,[22],"The purpose of this clinical trial is to compare the incidence of defects in the uterine wall at the site of the scar (niche) and surgical complications when using high-segment versus low-segment hysterotomy, with both cross-suturing and non-cross-suturing techniques, in pregnant patients undergoing their first cesarean section.\n\nResearchers will compare four arms:\n\n* Low Segment Hysterotomy + Crossed hysterorrhaphy\n* High Segment Hysterotomy + Crossed hysterorrhaphy\n* Low Segment Hysterotomy + Non-Crossed hysterorrhaphy\n* High Segment Hysterotomy + Non-Crossed hysterorrhaphy\n\nParticipants will:\n\n* Cesarean delivery\n* Attend a follow up appointment between 6 to 16 weeks post surgery where will be perform a transvaginal sonography.",[25],[108,109,110,111],"High segmental hysterotomy","Low segmental hysterotomy","Caesarean section","hysterotomy defects","2026-05-05",{"date":84,"type":35},{"date":115,"type":35},"2025-06-12",{"date":117,"type":19},"2027-08-31",{"name":119,"class":41},"Fundacion Clinica Valle del Lili",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":20,"phases":129,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":4},"100632923","conservative-management-of-placenta-accreta-spectrum-using-kasr-al-ainy-technique-with-or-without-hayman-sutures-100632923","NCT07519993","Conservative Management of Placenta Accreta Spectrum Using Kasr Al-Ainy Technique With or Without Hayman Sutures","Inclusion Criteria:\n\n* Age 18-40 years\n* Antenatal PAS diagnosis confirmed by TAS\u002FTVS\u002FDoppler\n* Eligible for conservative Kasr Al-Ainy surgery\n* Singleton pregnancy\n* Written informed consent\n\nExclusion Criteria:\n\n* Multiple pregnancy\n* Uterine fibroids\n* Previous cesarean myomectomy\n* Cervical accreta\n* Extensive parametrial or bladder invasion requiring hysterectomy\n* Known coagulopathy or uncorrected bleeding disorder.\n* Severe medical comorbidities rendering the patient unfit for major surgery under general anesthesia (e.g., severe cardiac or pulmonary disease)\n* Medical disorders as HTN and DM\n* Patient refusal","40 Years",{"count":128,"type":19},48,[22],"This study evaluates whether adding Hayman sutures in the conservative Management of Placenta Accreta Spectrum Using Kasr Al-Ainy Technique reduces intraoperative blood loss and improves outcomes",[25],"NOT_YET_RECRUITING","2026-04-02",{"date":135,"type":35},"2026-04-09",{"date":137,"type":19},"2026-04-05",{"date":139,"type":19},"2026-12-31",{"name":141,"class":41},"Cairo University",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":149,"targetDuration":151,"studyType":55,"phases":4,"briefSummary":152,"conditions":153,"keywords":156,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":167,"leadSponsor":169,"locationsCount":4},"100627711","evaluation-of-cervical-invasion-and-length-in-placenta-accreta-patients-100627711","NCT07452185","Evaluation of Cervical Invasion and Length in Placenta Accreta Patients","Evaluation of Placental Cervical Invasion and Cervical Length in Patients With Placenta Accreta","Inclusion Criteria:\n\n* Pregnant women aged 18-45 years with suspected or confirmed PAS based on prenatal ultrasound (e.g., placenta previa with at least one prior cesarean section).\n* Gestational age between 18-32 weeks at enrollment to allow for serial monitoring.\n* Singleton pregnancy.\n* High-risk features such as history of multiple cesarean sections, antepartum bleeding, or abnormal placental location on initial screening.\n\nExclusion Criteria:\n\n* Multiple gestation.\n* Pre-existing cervical incompetence or cerclage placement prior to enrollment. -Transfer from outside facilities without complete prenatal records.",{"count":150,"type":19},200,"16 Weeks","Placenta accreta spectrum (PAS), also called morbidly adherent placenta, is a serious pregnancy problem where the placenta attaches too deeply to the uterus wall and does not come out normally after birth. This often happens after previous cesarean sections or when the placenta is low (placenta previa). It can cause heavy bleeding, serious complications, and danger to the mother.\n\nThis study will look at pregnant women with PAS at Sohag University Hospital in Egypt. Researchers will use ultrasound to check two things:\n\nHow much the placenta has invaded the cervix (the lower part of the uterus). The length of the cervix.\n\nThe main goals are to find out:\n\nHow common cervical invasion is in PAS cases. What happens to women who have this invasion (outcomes like bleeding or surgery needs).\n\nIf a short cervix is linked to early labor (preterm birth). Women with confirmed PAS will join this observational study from March 2026 to January 2028. They will have extra ultrasound scans during pregnancy. No new treatments or drugs are tested - the study only collects information from routine care and scans to better understand the condition.\n\nThis research may help doctors predict risks earlier, plan safer deliveries, and improve care for mothers and babies with PAS in the future.",[25,154,155],"Placenta Accreta","Placenta Previa",[157,158,159,160,161,162],"Placenta accreta spectrum","Cervical invasion","Cervical length","Placenta accreta","Ultrasound evaluation","Preterm labor","2026-03-01",{"date":165,"type":35},"2026-03-05",{"date":163,"type":19},{"date":168,"type":19},"2028-01-01",{"name":170,"class":41},"Sohag University",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":179,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":181,"conditions":182,"keywords":183,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":4},"100624223","spinal-versus-general-anesthesia-in-pregnancies-with-placenta-accreta-spectrum-a-retrospective-comparative-study-100624223","NCT07406841","Spinal Versus General Anesthesia in Pregnancies With Placenta Accreta Spectrum: A Retrospective Comparative Study","Comparison of Spinal and General Anesthesia on Maternal and Neonatal Outcomes in Pregnancies With Placenta Accreta Spectrum: A Retrospective Study","SAGA-PAS","Inclusion Criteria:\n\n* Pregnant patients diagnosed with placenta accreta spectrum (PAS), Undergoing elective cesarean delivery, Receiving either spinal anesthesia or general anesthesia during cesarean section, Singleton pregnancy, Availability of complete medical and anesthesia records related to surgery and perioperative management\n\nExclusion Criteria:\n\nPatients without a diagnosis of PAS, Emergency (non-elective) cesarean deliveries, Use of anesthesia techniques other than spinal or general anesthesia, Multiple pregnancy (twins or more) ,Incomplete or missing medical\u002Fanesthesia records, Missing key perioperative or neonatal outcome data",{"count":180,"type":19},50,"Placenta accreta spectrum (PAS) is a serious pregnancy complication in which the placenta grows abnormally into the uterine wall. This condition is associated with a high risk of severe bleeding, need for blood transfusion, hysterectomy, and maternal complications during cesarean delivery.\n\nThis study aims to compare spinal anesthesia and general anesthesia in pregnant women diagnosed with placenta accreta spectrum who underwent cesarean delivery. The researchers reviewed existing medical records to evaluate differences in maternal and neonatal outcomes between the two anesthesia approaches.\n\nThe primary outcomes include changes in hemoglobin levels before and after surgery, the need for uterotonic medications during and after the operation, and newborn Apgar scores. Because this is a retrospective observational study, no new treatments were given, and all data were collected from routine clinical care records.\n\nThe findings are expected to help guide anesthetic decision-making in PAS cases, improve maternal and neonatal safety, and contribute to the international scientific literature on this topic.",[25],[157,184,185,186],"PAS","spinal anesthesia","general anesthesia","2026-02-11",{"date":189,"type":35},"2026-02-12",{"date":191,"type":19},"2026-02-01",{"date":193,"type":19},"2026-03-30",{"name":195,"class":41},"Gaziantep City Hospital",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":203,"targetDuration":4,"studyType":20,"phases":205,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":220},"100594938","planned-delivery-at-37-versus-36-weeks-in-pregnancies-with-placenta-previaand-accreta-100594938","NCT07025954","Planned Delivery at 37 Versus 36 Weeks in Pregnancies With Placenta Previaand Accreta","Planned Delivery at 37 Versus 36 Weeks in Pregnancies Complicated byPlacenta Previa and Accreta: A Randomized Controlled Trial","Inclusion Criteria:\n\n* 28-34 weeks of gestation.\n* Both ultrasound and MRI indicate placenta previa with placenta accreta spectrum (PAS).\n* Planned to undergo cesarean delivery at the participating study hospitals.\n* Agree to participate and sign the informed consent form.\n\nExclusion Criteria:\n\n* Multiple gestation.\n* Other obstetric complications (e.g., preeclampsia, vasa previa), and severe maternal medical conditions (e.g., uncontrolled diabetes, progressive cardiovascular disease, active systemic lupus erythematosus, liver cirrhosis).\n* Major uterine structural anomalies (e.g., uterine didelphys, Uterine tumors ≥5 cm).\n* Estimated fetal weight \\\u003C3rd percentile for gestational age, major congenital anomalies, intrauterine fetal demise.",{"count":204,"type":19},600,[22],"Current clinical practice guidelines recommend planned cesarean delivery(CD) at 34-37 weeks of gestation in pregnant women with placenta previa and accreta. Preterm birth may lead to neonatal immaturity, while laterCD may increase the risk of severe hemorrhage and surgery complications. Retrospective studies have shown that indicated CD occurs in approximately1\u002F3 of patients before 36 weeks, with the main trigger being antepartum hemorrhage. However, the risk of antepartum hemorrhage is lower after 36 weeks. Recent study showed that delivery shifted from 34-36 weeks to 37 weeks did not increase therisk of maternal intraoperative\u002Fpostoperative hemorrhage and emergency CD. To further validate this, we propose to conduct a randomized controlled study comparing the effect of planned delivery management strategies at 37 0\u002F7-37 6\u002F7 weeks of gestation with those at 36 0\u002F7-36 6\u002F7 weekson maternal and fetal outcomes. The aim of this study is to explore whether planned delivery up to 37 weeks in pregnant women with placenta previa and accreta improves neonatal outcomes without increasing maternal obstetric risks.",[155,25,208,209,210],"Antepartum Bleeding","Emergency Cesarean Section","Preterm Birth Complication","2025-07-11",{"date":213,"type":35},"2025-07-16",{"date":215,"type":35},"2025-07-12",{"date":217,"type":19},"2027-03-01",{"name":219,"class":41},"The Third Affiliated Hospital of Guangzhou Medical University",6,{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":184,"eligibilityCriteria":227,"healthyVolunteers":101,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":20,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":239,"locationsCount":42},"100582789","syncytiotrophoblast-derived-extracellular-vesicles-in-placenta-previa-and-accreta-spectrum-100582789","NCT06867874","Syncytiotrophoblast-derived Extracellular Vesicles in Placenta Previa and Accreta Spectrum","Shedding of Syncytiotrophoblast-derived Extracellular Vesicles is Increased in Placenta Previa and Accreta Spectrum: a Case-control Study.","Inclusion Criteria:\n\n* Pregnant women with diagnosis of placenta previa and accreta spectrum (cases)\n* Healthy pregnant women\n* \\> 18 years\n\nExclusion Criteria:\n\n* \\\u003C 18 years\n* Twin pregnancies\n* Chronic Infections\n* Cancers\n* Unable to give the written consent",{"count":229,"type":19},70,[22],"The main goal of this case-control study is to quantify the levels of circulating syncytiotrophoblast-derived extracellular vesicles (STBEVs) in maternal blood in a population of women with placenta previa and placenta accreta spectrum.",[155,25],"2025-03-05",{"date":235,"type":35},"2025-03-10",{"date":237,"type":35},"2023-07-10",{"date":163,"type":19},{"name":240,"class":41},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":184,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":248,"maxAge":126,"enrollmentInfo":249,"targetDuration":4,"studyType":20,"phases":251,"briefSummary":252,"conditions":253,"keywords":254,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":42},"100429039","placenta-accreta-spectrum-outcome-after-uterine-conservation-100429039","NCT04866888","Placenta Accreta Spectrum Outcome After Uterine Conservation","Short and Intermediate Term Outcomes of Uterine Conservation After Cesarian Section in Cases of Placenta Accreta Spectrum","Inclusion Criteria:\n\n* • Diagnosed sonographically to have placenta accreta spectrum.\n\n  * Pregnancy is singleton and fetus is alive.\n  * Elective caesarean section done from 35 gestational weeks.\n\nExclusion Criteria:\n\n* • Patients requesting hysterectomy.\n\n  * Coexisting uterine pathology such as fibroids or gynaecological malignancies.\n  * Patients with bleeding diathesis.\n  * Morbid obesity of BMI \\>40.\n  * Patients having labour pains or vaginal bleeding before scheduled intervention.","20 Years",{"count":250,"type":19},120,[22],"study will be carried out on patients with placenta accreta spectrum having done uterine conservation and recording immediate outcome of conservation regarding success of the procedure, amount of blood loss and amount of blood transfused and followed up to check the return of menses, any uterine abnormalities by ultrasound or hysteroscopy especially isthmocele and intrauterine synechia.",[25],[184],"2025-02-11",{"date":257,"type":35},"2025-02-12",{"date":259,"type":35},"2021-04-28",{"date":261,"type":19},"2026-03-15",{"name":263,"class":41},"Alexandria University",{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":271,"targetDuration":4,"studyType":20,"phases":273,"briefSummary":274,"conditions":275,"keywords":276,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":4},"100571509","effectiveness-of-reboa-in-reducing-blood-loss-during-cesarean-section-in-patients-with-pas-100571509","NCT06721182","Effectiveness of REBOA in Reducing Blood Loss During Cesarean Section in Patients with PAS","Effectiveness of Endovascular Balloon Occlusion of the Aorta in Reducing Blood Loss During Cesarean Section in Patients with Placenta Accreta Spectrum Disorders in Tertiary Care Center in Kazakhstan: a Randomized Controlled Trial","Inclusion Criteria: (1) singleton pregnancy at 34 weeks of gestation or more, (2) age 18 to 45 years, (3) confirmed diagnosis of placenta accreta spectrum, (4) indication for elective cesarean section, (5) consent for aortic balloon occlusion during cesarean section -\n\nExclusion Criteria:(1) pregnant patients at the gestational age ˂ 34 weeks of gelation, (2) multiple pregnancy, (3) need for emergency caesarean section, (4) coagulopathy (known coagulopathy, women with abnormal baseline activated partial thromboplastin time (aPTT), prothrombin time (PT), international normalization ratio (INR) before surgery)\n\n\\-",{"count":272,"type":19},100,[22],"Obstetric hemorrhage is one of the leading causes of maternal mortality and morbidity worldwide. The major risk factors for obstetric hemorrhage include placenta previa and placenta accreta spectrum (PAS) disorders. The frequency of PAS disorders is increasing worldwide and is accompanied by intraoperative massive bleeding with hemorrhagic shock and increasing rates of cesarean hysterectomy. To decrease risks of bleeding, various approached of endovascular balloon occlusion are tested during the recent decade. This study aims to evaluate the effectiveness of resuscitative endovascular balloon occlusion of the aorta (REBOA) in reducing blood loss and preserving the reproductive organs during cesarean section. This will be a prospective randomized controlled trial involving 100 patients in tertiary care obstetric center in Kazakhstan. The study population will consist of pregnant women who will be admitted to the University Medical Center for cesarean section due to placenta previa complicated by PAS disorders. Study subjects will be randomly divided in intervention and control groups. The results will be analyzed through the measurement of primary (blood loss during cesarean section) and secondary outcomes \\[occurrence of hysterectomy during cesarean section, blood transfusion volume, duration of surgery, balloon application time, stay in intensive care unit (ICU), neonatal outcomes, complications, and total days of postsurgical hospital stay\\]. Use of REBOA is expected to minimize intraoperative blood loss during cesarean section, decrease the need for transfusion of blood components, reduce the time of surgical intervention, and decrease the rate of maternal complications and reduce the rate of cesarean hysterectomy.",[25],[277,278,279,280,281,282,283,284],"REBOA","obstetric hemorrhage","cesarean hysterectomy","placenta accreta spectrum","clinical outcome","cesarean section","endovascular balloon occlusion","abnormally invasive placenta","2024-12-03",{"date":287,"type":35},"2024-12-06",{"date":289,"type":19},"2024-12-20",{"date":291,"type":19},"2026-12-01",{"name":293,"class":41},"Nazarbayev University",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":101,"sex":16,"minAge":248,"maxAge":126,"enrollmentInfo":301,"targetDuration":4,"studyType":20,"phases":302,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":42},"100554044","role-of-uterotonics-in-reducing-intraoperative-blood-loss-in-patients-with-pasd-undergoing-cesarean-hysterectomy-100554044","NCT06493968","Role of Uterotonics in Reducing Intraoperative Blood Loss in Patients With PASD Undergoing Cesarean Hysterectomy","Role of Uterotonics in Reducing Intraoperative Blood Loss in Patients With Placenta Accrete Spectrum Disorders Undergoing Cesarean Hysterectomy","Inclusion Criteria:\n\n* Pregnancy of singleton living fetus\n* Previous one or more cesarean sections\n* Gestational age: \\> 32 weeks\n* The following ultrasound markers such as \"loss of clear retroplacental translucency\", \"myometrial thinning\", \"abnormal lacunae\", \"irregular bladder wall\", \"utero-vesicalhypervascularity\".\n* Preoperative hemoglobin more than 10 gm\u002Fdl\n* Cases with PAS that will undergoing CS Hysterectomy\n\nExclusion Criteria:\n\n* Maternal medical disorders e.g.: coagulation defects, cardiac diseases etc.….\n* Any known or reported hypersensitivity to the used medication.\n* All cases with spontaneous placental separation at laparotomy.\n* All patients undergoing conservative management of PAS.\n* All cases which necessitate emergency termination.",{"count":229,"type":19},[22],"Objectives: To evaluate the effect of oxytocin in reducing intraoperative blood loss in patients with PAS disorders planned for cesarean hysterectomy.",[25],"2024-07-02",{"date":307,"type":35},"2024-07-10",{"date":309,"type":35},"2024-07-01",{"date":311,"type":19},"2024-12-31",{"name":141,"class":41},{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":20,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":329,"leadSponsor":331,"locationsCount":4},"100553256","comparison-between-cervical-tourniquet-and-uterine-artery-ligation-prior-to-segmental-resection-approach-100553256","NCT06483724","Comparison Between Cervical Tourniquet and Uterine Artery Ligation Prior to Segmental Resection Approach","Comparison Between Cervical Tourniquet and Uterine Artery Ligation Prior to the Segmental Resection Approach in Patients With Placenta Accreta Spectrum: A Prospective Interventional Study","Inclusion Criteria:\n\n* Diagnosed sonographically to have placenta accreta spectrum .\n* Pregnancy is singleton and fetus is alive.\n* Elective caesarean section done from 36 gestational weeks\n\nExclusion Criteria:\n\n* Patients requesting hysterectomy\n* Coexisting uterine pathology such as fibroids or gynaecological malignancies\n* Patients with bleeding diathesis.\n* Morbid obesity of BMI \\>40.\n* Patients having labour pains or vaginal bleeding before scheduled intervention","38 Years",{"count":322,"type":19},82,[22],"The study will compare a modified surgical approach for preserving fertility and minimizing hemorrhage in morbidly adherent placenta during cesarean section with a cervical tourniquet against uterine artery ligation.",[25],{"date":327,"type":35},"2024-07-05",{"date":309,"type":19},{"date":330,"type":19},"2025-05-01",{"name":332,"class":41},"Minia University",{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":101,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":341,"conditions":342,"keywords":343,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":349,"leadSponsor":351,"locationsCount":4},"100552777","the-application-of-comprehensive-prevention-and-treatment-strategy-of-placenta-accreta-spectrum-disorders-100552777","NCT06477497","The Application of Comprehensive Prevention and Treatment Strategy of Placenta Accreta Spectrum Disorders","Inclusion Criteria:\n\n* Pregnant women who have regular prenatal examination at the research hospitals\n* Pregnant women diagnosed with PAS before or after delivery\n\nExclusion Criteria:\n\n* Pregnant women who have never been diagnosed with placental implantation disease throughout the pregnancy\n* Pregnant women who were lost to follow-up during the study period",{"count":340,"type":19},33,"Placenta accreta spectrum (PAS) disorders are pathological attachment of the placenta to myometrium, where trophoblastic cells invade the uterine placental interface. PAS can lead to severe postpartum hemorrhage or even maternal death. Prenatal diagnosis of PAS is essential for optimal obstetric management to improve the pregnancy outcomes. However, in some low resource regions in China, less than 20% PAS are detected before delivery.\n\nTo explore the feasibility and universality of the bundled prevention and treatment strategy for placenta accreta spectrum disorders in different levels of medical institutions, and to investigate its effectiveness in improving the specialized disease management capabilities of medical institutions at all levels. We will conduct a regional, cluster-randomized trial to assess a multicomponent PAS management strategy to improve the prepartum detection rate of PAS.",[25],[344],"placenta accreta spectrum disorders","2024-06-26",{"date":347,"type":35},"2024-06-27",{"date":309,"type":19},{"date":350,"type":19},"2025-11-30",{"name":352,"class":41},"Peking Union Medical College Hospital"]